Germline and somatic smoothened mutations in non-small-cell lung cancer are potentially responsive to hedgehog inhibitor vismodegib

Tsao, Anne S.; Wistuba, Ignacio Ivans; Xia, Dianren; Byers, Lauren Averett; Diao, Lixiao; Wang, Jing; Papadimitrakopoulou, Vassiliki A.; Tang, Ximing; Lu, Wei; Kadara, Humam N.; Grigoryev, Dimitry N.; Esai Selvan, Myvizhi Esai; Gümüş, Zeynep Hülya; Tan, Zhi; Zhang, Shuxing; Nilsson, Monique B.; Heymach, John Victor

doi:https://doi.org/10.1200/PO.17.00149

Germline and somatic smoothened mutations in non-small-cell lung cancer are potentially responsive to hedgehog inhibitor vismodegib

Date

2017

Authors

Tsao, Anne S.

Wistuba, Ignacio Ivans

Xia, Dianren

Byers, Lauren Averett

Diao, Lixiao

Wang, Jing

Papadimitrakopoulou, Vassiliki A.

Tang, Ximing

Lu, Wei

Kadara, Humam N.

Publisher

American Society of Clinical Oncology

Keywords

8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one, Cisplatin, Erlotinib, Etoposide, Smoothened protein, Vismodegib, Adult, Aged, Article, Basal cell carcinoma, Cancer radiotherapy, Case report, Child, Clinical article, Drug response, Exon, Female, Germline mutation, Histopathology, Human, Human cell, Human tissue, Lung adenocarcinoma, Lung biopsy, Male, Molecular diagnosis, Multiple cycle treatment, Non small cell lung cancer, Nonsmoker, Palliative therapy, Pedigree analysis, Preschool child, Priority journal, Smo gene, Somatic mutation, Squamous cell lung carcinoma